Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Oct 16;16(1):134.
doi: 10.1186/s12933-017-0617-4.

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials

Marit de Jong  1 , H Bart van der Worp  2 , Yolanda van der Graaf  3 , Frank L J Visseren  4 , Jan Westerink  5
Affiliations
Meta-Analysis

Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials

Marit de Jong et al. Cardiovasc Diabetol. .

Abstract

Background and aims: Pioglitazone targets multiple pathogenic pathways involved in the development of cardiovascular diseases (CVD). The aim of this systematic review and meta-analysis is to assess the effects of pioglitazone treatment on the secondary prevention of CVD.

Methods: Randomized-controlled trials of pioglitazone in patients with CVD were identified through PubMed, Embase, Cochrane and CINAHL, in a search up to May 2016. Studies were included if pioglitazone was compared with any control (usual care, placebo or active comparator) and if patients were previously diagnosed with CVD. The outcomes of interest included major adverse cardiovascular events (MACE), myocardial infarction (MI), stroke, all-cause mortality and heart failure (HF). All outcomes were compared by pooled risk ratios (RR) with a 95% confidence interval (CI). Pooled estimates were calculated using a random-effects model.

Results: Ten studies reported the effects of pioglitazone on any of the outcomes of interest. Pioglitazone reduced recurrent MACE (RR 0.74, 95% 0.60-0.92; I2 = 35), MI (RR 0.77, 95% CI 0.64-0.93; I2 = 0%), or stroke (RR 0.81, 95% CI 0.68-0.96; I2 = 0%). Pioglitazone did not reduce all-cause mortality (RR 0.94, 95% CI 0.81-1.08; I2 = 0%), whereas pioglitazone treatment was associated with an increased risk of HF (RR 1.33, 95% CI 1.14-1.54).

Conclusions: Pioglitazone lowers the risk of recurrent MACE, stroke, or MI in patients with clinical manifest vascular disease. Pioglitazone does not lower the risk for all-cause mortality, and increases the risk for the development of HF.

Keywords: Cardiovascular disease; Pioglitazone; Secondary prevention.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flowchart
Fig. 2
Fig. 2
Forrest plots. Forrest plot for the effects of pioglitazone on major adverse cardiac/cardiovascular events (a), a composite of nonfatal myocardial infarction, nonfatal stroke and cardiovascular mortality (b) and myocardial infarction (c)
Fig. 3
Fig. 3
Forrest plots. Forrest plot for the effects of pioglitazone on stroke (a), stroke recurrence (b), all-cause mortality (c) and heart failure (d)
See this image and copyright information in PMC

References

    1. Dhamoon MS, Sciacca RR, Rundek T, Sacco RL, Elkind MS. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology. 2006;66:641–646. doi: 10.1212/01.wnl.0000201253.93811.f6. - DOI - PubMed
    1. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321–1331. doi: 10.1056/NEJMoa1506930. - DOI - PMC - PubMed
    1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–e60. doi: 10.1161/CIR.0000000000000350. - DOI - PubMed
    1. WHO. The top 10 causes of death. 2016. http://www.who.int/mediacentre/factsheets/fs310/en/. Accessed 4 May 2016.
    1. Kessler T, Vilne B, Schunkert H. The impact of genome-wide association studies on the pathophysiology and therapy of cardiovascular disease. EMBO Mol Med. 2016;8:688–701. doi: 10.15252/emmm.201506174. - DOI - PMC - PubMed

MeSH terms